Consolidated Alcon Eye Division Has Key Role In Maintaining Novartis’ Growth

Like many other big pharma companies, Novartis AG faces an imminent patent cliff, with blood pressure blockbuster Diovan (valsartan), among other products, due to lose patent protection soon.